Association between vitamin D receptor (VDR) polymorphisms and the risk of multiple sclerosis (MS): an updated meta-analysis

Imani, Danyal; Razi, Bahman; Motallebnezhad, Morteza; Rezaei, Ramazan

doi:10.1186/s12883-019-1577-y

Table 1 Characteristics of studies included in Meta-analysis of overall MS

From: Association between vitamin D receptor (VDR) polymorphisms and the risk of multiple sclerosis (MS): an updated meta-analysis

Study author	Year	Country	Ethnicity	Sex cases/controls	Total cases/control	Age case/control (Mean)	Genotyping method	Quality score
FokI (rs2228570)
Partridge et al.	2004	UK	European	M = NR F=NR	406 /234	43.8 ± 11.2 / 50.1	NR	7
Tajouri et al.	2005	Australia	Australian	M = NR F=NR	98 / 93	NR	PCR–RFLP	6
Smolders et al.	2009	Netherland	European	M = 62/ 142 F = 150/ 147	212 / 289	46.7 ± 11.9 /34.9 ± 14.3	PCR–RFLP	8
Dickinson et al.	2009	Australia	Australian	M = NR F=NR	136 / 235	43.5 ± 9.3/ 43.6 ± 9.2	Taq-Man	7
Simon et al.	2010	USA	American	M = NR F=NR	100 / 100	NR	Taq-Man	7
Garcia-Martin et al.	2013	Spain	European	M = 94/ 98 F = 209/ 212	303 / 310	43.9 ± 11.4/ 43.4 ± 11.7	Taq-Man	8
Al-Temaimi et al.	2015	Kuwait	Asian	M = 17/ 19 F = 33/ 31	50 / 50	33.4 ± 9.6/ 28.6 ± 7.9	Taq-Man	7
Narooie-Nejad et al.	2015	Iran	Asian	M = 25 / 28 F = 88/ 94	113 / 122	32.4 ± 8.9/ 30.8 ± 10.2	PCR–RFLP	7
Cierny et al.	2015	Slovakia	European	M = 66 / 74 F = 204 / 229	270 / 303	41.3 ± 10.8/ 38.7 ± 13.6	PCR–RFLP	8
Luisa Agnello et al.	2016	Italy	European	M = 24 / 30 F = 80 / 42	104 / 75	39.6 ± 10.3/ 45.2 ± 9.36	PCR–RFLP	6
Abdollahzadeh et al.	2016	Iran	Asian	M = 40 / 38 F = 120 / 112	160 / 150	35.9 ± 3 / 36.8 ± 1.8	PCR–RFLP	7
Yucel et al.	2017	Turkey	European	M = NRF=NR	29 / 114	33.7 ± 10.7 / 33.1 ± 8.5	Taq-Man	6
Bettencourt et al.	2017	Portugal	European	M = 185/198 F = 348/248	533 / 446	30.2 ± 9.3/ NR	Taq-Man	8
Kamisli et al.	2018	Turkey	European	M = 46 / 58 F = 121 / 88	167 / 146	39.96 ± 9.4 / 33.81 ± 7.1	Taq-Man	7
Sadeghi et al.	2018	Iran	Asian	M = 17/11 F = 63/39	80 / 50	18–60/ 18–60	PCR–RFLP	6
Křenek et al.	2018	Czech Republic	European	M = 80/49 F = 216/86	296/135	34–37 / NR	PCR–RFLP	7
TaqI (rs731236)
Partridge et al.	2004	UK	European	M = NR F=NR	402 /231	43.8 ± 11.2 / 50.1	NR	7
Tajouri et al.	2005	Australia	Australian	M = NR F=NR	104 / 186	NR	PCR–RFLP	6
Smolders et al.	2009	Netherland	European	M = 62/ 142 F = 150/ 147	212 / 289	46.7 ± 11.9 /34.9 ± 14.3	PCR–RFLP	8
Dickinson et al.	2009	Australia	Australian	M = NR F=NR	136 / 235	43.5 ± 9.3/ 43.6 ± 9.2	Taq-Man	7
Simon et al.	2010	USA	American	M = NR F=NR	100 / 100	NR	Taq-Man	7
Sioka et al.	2011	Greece	European	M = 23/ 23 F = 46/ 58	69 / 81	39 ± 10.5/38.7 ± 10.7	Taq-Man	7
Agliardi et al.	2011	Italy	European	M = NR F=NR	641 / 558	27.8 ± 9.2/ 29.4 ± 6.5	Taq-Man	8
Irizar et al.	2012	Spain	European	M = NR F=NR	136 / 337	44.14 ± 13.02/ 50.17 ± 13.26	PCR-SSP	7
Garcia-Martin et al.	2013	Spain	European	M = 94/ 98 F = 209/ 212	303 / 310	43.9 ± 11.4/ 43.4 ± 11.7	Taq-Man	8
Selma et al.	2015	Tunisia	African	M = 22/ 47 F = 38/ 67	60 / 114	35.8 ± 6.3 / 37 ± 9.3	PCR–RFLP	6
Narooie-Nejad et al.	2015	Iran	Asian	M = 25 / 28 F = 88/ 94	113 / 122	32.4 ± 8.9/ 30.8 ± 10.2	PCR–RFLP	7
Al-Temaimi et al.	2015	Kuwait	Asian	M = 17/ 19 F = 33/ 31	50 / 50	33.4 ± 9.6/ 28.6 ± 7.9	Taq-Man	7
Yamout et al.	2016	Lebanon	Asian	M = NR F=NR	50 / 99	32.3 ± 12.7 / 35.2 ± 13	PCR–RFLP	6
Cierny et al.	2016	Slovakia	European	M = 66 / 74 F = 204 / 229	270 / 303	41.3 ± 10.8/ 38.7 ± 13.6	PCR–RFLP	8
Luisa Agnello et al.	2016	Italy	European	M = 24 / 30 F = 80 / 42	104 / 75	39.6 ± 10.3/ 45.2 ± 9.36	PCR–RFLP	6
Terzi et al.	2016	Turkey	European	M = NR F=NR	87 / 99	30.14 9.66/ NR	PCR–RFLP	6
Abdollahzadeh et al.	2016	Iran	Asian	M = 40 / 38 F = 120 / 112	160 / 150	35.9 ± 3 / 36.8 ± 1.8	PCR–RFLP	7
Yucel et al.	2017	Turkey	European	M = NR F=NR	28 / 72	33.7 ± 10.7 / 33.1 ± 8.5	Taq-Man	6
Kamisli et al.	2018	Turkey	European	M = 46 / 58 F = 121 / 88	167 / 146	39.96 ± 9.4 / 33.81 ± 7.1	Taq-Man	7
Morales et al.	2018	Mexico	American	M = 39/ 57 F = 81/123	120 / 180	33.89 ± 10.03/ 32.79 ± 10.17	Taq-Man	6
Sadeghi et al.	2018	Iran	Asian	M = 17/11 F = 63/39	80 / 50	18–60/ 18–60	PCR–RFLP	6
Cakina et al..	2018	Turkey	European	M = 19/22 F = 51/48	70 / 70	44.4 ± 11.2 / 38.2 ± 9.5	PCR–RFLP	7
Křenek et al.	2018	Czech Republic	European	M = 80/49 F = 216/86	296 / 135	34–37 / NR	PCR–RFLP	7
BsmI (rs1544410)
Fukazawa et al.	1999	Japan	Asian	M = 21/33 F = 56/62	77 / 95	34.9 ± 12.9/NR	PCR–RFLP	8
Qinli Sun et al.	2004	China	Asian	M = NR F=NR	63 / 95	NR	PCR–RFLP	6
Bing Wu et al.	2009	China	Asian	M = NR F=NR	83 / 120	NR	PCR–RFLP	7
Simon et al.	2010	USA	American	M = NR F=NR	101 / 100	NR	Taq-Man	7
Sioka et al.	2011	Greece	European	M = 23/ 23 F = 46/ 58	69 / 81	39 ± 10.5/38.7 ± 10.7	Taq-Man	7
Al-Temaimi et al.	2015	Kuwait	Asian	M = 17/ 19 F = 33/ 31	50 / 50	33.4 ± 9.6/ 28.6 ± 7.9	Taq-Man	7
Narooie-Nejad et al.	2015	Iran	Asian	M = 25 / 28 F = 88/ 94	113 / 122	32.4 ± 8.9/ 30.8 ± 10.2	PCR–RFLP	7
Abdollahzadeh et al.	2016	Iran	Asian	M = 40 / 38 F = 120 / 112	160 / 150	35.9 ± 3 / 36.8 ± 1.8	PCR–RFLP	7
Yamout et al.	2016	Lebanon	Asian	M = NR F=NR	50 / 99	32.3 ± 12.7 / 35.2 ± 13	PCR–RFLP	6
Cierny et al.	2016	Slovakia	European	M = 66 / 74 F = 204 / 229	270 / 303	41.3 ± 10.8/ 38.7 ± 13.6	PCR–RFLP	8
Luisa Agnello et al.	2016	Italy	European	M = 24 / 30 F = 80 / 42	104 / 75	39.6 ± 10.3/ 45.2 ± 9.36	PCR–RFLP	6
Terzi et al.	2016	Turkey	European	M = NR F=NR	87 / 100	30.14 ± 9.66/ NR	PCR–RFLP	6
Morales et al.	2017	Mexico	American	M = 39/ 57 F = 81/123	120 / 180	33.89 ± 10.03/ 32.79 ± 10.17	Taq-Man	6
Sadeghi et al.	2018	Iran	Asian	M = 17/11 F = 63/39	80 / 50	18–60/ 18–60	PCR–RFLP	6
Cakina et al..	2018	Turkey	European	M = 19/22 F = 51/48	70 / 70	44.4 ± 11.2 / 38.2 ± 9.5	PCR–RFLP	7
Křenek et al.	2018	Czech Republic	European	M = 80/49 F = 216/86	296 / 135	34–37 / NR	PCR–RFLP	7
ApaI (rs7975232)
Niino et al.	2000	Japan	Asian	M = 21 / 33 F = 56 / 62	77 / 95	36.2 ± 11.2 / 34.4 ± 10.2	PCR–RFLP	7
Qinli Sun et al.	2004	China	Asian	M = NR F=NR	63 / 95	NR	PCR–RFLP	6
Tajouri et al.	2005	Australia	Australian	M = NR F=NR	104 / 100	NR	PCR–RFLP	6
Smolders et al.	2009	Netherland	European	M = 62/ 142 F = 150/ 147	212 / 289	46.7 ± 11.9 /34.9 ± 14.3	PCR–RFLP	8
Bing Wu et al.	2009	China	Asian	M = NR F=NR	83 / 120	NR	PCR–RFLP	7
Simon et al.	2010	USA	American	M = NR F=NR	100 / 100	NR	Taq-Man	7
Irizar et al.	2012	Spain	European	M = NR F=NR	134 / 340	44.14 ± 13.02/ 50.17 ± 13.26	PCR-SSP	7
Narooie-Nejad et al.	2015	Iran	Asian	M = 25 / 28 F = 88/ 94	113 / 122	32.4 ± 8.9/ 30.8 ± 10.2	PCR–RFLP	7
Al-Temaimi et al.	2015	Kuwait	Asian	M = 17/ 19 F = 33/ 31	50 / 50	33.4 ± 9.6/ 28.6 ± 7.9	Taq-Man	7
Selma et al.	2015	Tunisia	African	M = 22/ 47 F = 38/ 67	60 / 114	35.8 ± 6.3 / 37 ± 9.3	PCR–RFLP	6
Yamout et al.	2016	Lebanon	Asian	M = NR F=NR	50 / 134	32.3 ± 12.7 / 35.2 ± 13	PCR–RFLP	6
Luisa Agnello et al.	2016	Italy	European	M = 24 / 30 F = 80 / 42	104 / 75	39.6 ± 10.3/ 45.2 ± 9.36	PCR–RFLP	6
Abdollahzadeh et al.	2016	Iran	Asian	M = 40 / 38 F = 120 / 112	160 / 150	35.9 ± 3 / 36.8 ± 1.8	PCR–RFLP	7
Cierny et al.	2016	Slovakia	European	M = 66 / 74 F = 204 / 229	270 / 303	41.3 ± 10.8/ 38.7 ± 13.6	PCR–RFLP	8
Terzi et al.	2016	Turkey	European	M = NR F=NR	87 / 100	30.14 9.66/ NR	PCR–RFLP	6
Yucel et al.	2017	Turkey	European	M = NR F=NR	26 / 81	33.7 ± 10.7 / 33.1 ± 8.5	Taq-Man	6
Kamisli et al.	2018	Turkey	European	M = 46 / 58 F = 121 / 88	167 / 146	39.96 ± 9.4 / 33.81 ± 7.1	Taq-Man	8
Sadeghi et al.	2018	Iran	Asian	M = 17/11 F = 63/39	80 / 50	18–60/ 18–60	PCR–RFLP	7
Cakina et al..	2018	Turkey	European	M = 19/22 F = 51/48	70 / 70	44.4 ± 11.2 / 38.2 ± 9.5	PCR–RFLP	7
Křenek et al.	2018	Czech Republic	European	M = 80/49 F = 216/86	296 / 135	34–37 / NR	PCR–RFLP	7

NR not reported, M male, F female, MS Multiple Sclerosis

Back to article page

ISSN: 1471-2377

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Neurology

Contact us